ST. LOUIS, April 23, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has successfully enrolled and scanned patients in its SOLAR clinical trials: The first trial is SOLAR-STAGE: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in staging of men with newly diagnosed unfavorable intermediate-risk, high-risk or very-high-risk prostate cancer electing to undergo radical prostatectomy with pelvic lymph node dissection.The second study, SOLAR-RECUR: a Phase 3, multicenter, open-label study to evaluate the diagnostic performance of copper Cu 64 PSMA I&T PET/CT in men with suspected biochemical recurrence of prostate cancer after radical prostatectomy or radiation therapy.

圣路易斯，2024年4月23日（环球通讯社）--世界核医学领导者库里姆今天宣布，它已成功招募和扫描患者参加其太阳能临床试验：第一项试验是太阳能阶段：一项3期，多中心，开放标签研究，以评估铜铜铜64 PSMA I＆T PET/CT在新诊断为不利的中危，高危或极高危前列腺癌的男性分期中的诊断性能，选择进行根治性前列腺切除术并进行盆腔淋巴结清扫。第二项研究，SOLAR-RECUR：一项3期多中心开放标签研究，用于评估铜Cu 64 PSMA I＆T PET/CT在根治性前列腺切除术或放射治疗后疑似前列腺癌生化复发的男性中的诊断性能。

These clinical trials are currently enrolling patients at sites across the U.S. and will be opening clinical trial sites in Europe later this year. Sakir Mutevelic, MD, Curium’s Chief Medical Officer said: “The successful start of patient enrollment is a significant step forward for Curium’s Phase 3 SOLAR-STAGE and SOLAR-RECUR clinical trials.

这些临床试验目前正在美国各地招募患者，并将于今年晚些时候在欧洲开设临床试验地点。Curium首席医疗官Sakir Mutevelic医学博士说：“患者登记的成功开始是Curium第三阶段太阳能阶段和太阳能复发临床试验的重要一步。

As we continue Curium’s journey to redefine the experience of cancer through our trusted legacy in nuclear medicine, we look forward to building on our well-established and successful 64-Cu diagnostic imaging platform.” Amy Bartalotta, Vice President of Clinical Operations added: “To ensure that the SOLAR clinical trials recruit a diverse set of patients – including minority groups that are often more affected by and less likely to be screened for prostate cancer – we have 50 sites in the U.S.

随着我们继续库里姆的旅程，通过我们在核医学领域值得信赖的遗产重新定义癌症的经验，我们期待着建立在我们完善且成功的64 Cu诊断成像平台上。”临床运营副总裁艾米·巴塔洛塔（AmyBartalotta）补充道：“为了确保太阳能临床试验招募多种患者，包括经常受前列腺癌影响较大且不太可能接受前列腺癌筛查的少数群体，我们在美国有50个站点。

and over 30 sites in Europe participating in these trials. We are pleased to announce the first patients enrolled and scanned were at XCancer® under the direction of Dr. L.

欧洲有30多个网站参与了这些试验。我们很高兴地宣布，在L博士的指导下，首批登记和扫描的患者在XCancer®进行。